Company Overview and News

12
Tough markets hit BlackRock results; shares slump 4 percent

2018-10-16 reuters
(Reuters) - BlackRock Inc’s (BLK.N) quarterly revenue fell short of Wall Street’s expectations on Tuesday as the world’s biggest asset manager reported its lowest sales of equity, bond and other long-term investments since the second quarter of 2016.
STT LLOY LYG LLPH LLPK BLK LLPJ LLPE LLOBF LLPD LLPG LLDTF LLD5 BEN LLD7 LLPC LLD6 LLD1 LLD2

11
Investor jitters hits world's biggest asset manager as $3bn pulled 

2018-10-16 telegraph.co.uk
Shares in the world's biggest asset manager BlackRock have slipped after it emerged that spooked investors pulled more than $3bn (£2.2bn) from its products.
LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

11
BlackRock wins US$40bil contract

2018-10-13 thestar.com.my
LONDON: Lloyds Banking Group has awarded BlackRock a £30bil (US$40bil) slice of one of Europe’s biggest investment contracts to be invested using the US company’s various index strategies.
SLFPF LLOY ADN SL LYG ABDNY LLPH LLPK LLPJ LLPE LLOBF LLPD LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 ABDNF LLD2 SLFPY

11
Blackrock wins chunk of Lloyd's contract pulled from Standard Life Aberdeen

2018-10-12 telegraph.co.uk
Lloyds Banking Group has handed the world's biggest fund manager a £30bn investment contract after axing its deal with Standard Life Aberdeen.
SLFPF LLOY SL LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2 SLFPY

11
LYG / Lloyds Banking Group plc FORM 6-K (Current Report of Foreign Issuer)

2018-10-11 sec.gov
FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
LYG

11
Blackstone poised to acquire NEC Group

2018-10-11 telegraph.co.uk
The multinational private equity company Blackstone is poised to acquire the live event and exhibition operator NEC Group in a deal worth more than $800m.
55KJ LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

17
Europe May Be Entering Its Third Stagnation In A Decade

2018-10-09 seekingalpha
While we have been proudly boasting of U.S. growth rates exceeding 4%, European growth rates have been receding. Europe’s second-quarter 2018 cumulative 12-month rate is 2.2%. (The following chart measures quarter-over-quarter increases, so the preceding four quarters added together equal 2.2%.)
WFC BBT WFCNP DB LYG

11
Schroders targets British wealth boost with Lloyds tie-up

2018-10-08 channelnewsasia
Schroders could soon help manage the money of people with significantly less in their bank accounts than the super-rich it has targeted so far, if talks with Lloyds about a wealth management tie-up succeed.
LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

11
Schroders targets British wealth boost with Lloyds tie-up

2018-10-08 reuters
LONDON (Reuters) - Schroders (SDR.L) could soon help manage the money of people with significantly less in their bank accounts than the super-rich it has targeted so far, if talks with Lloyds (LLOY.L) about a wealth management tie-up succeed.
LLOY LYG LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2

126
Oakmark Global Fund: Third Quarter 2018

2018-10-08 seekingalpha
Oakmark Global Fund – Investor Class Average Annual Total Returns (09/30/18) Since Inception (08/04/99) 10.18% 10–year 8.44% 5–year 6.33% 1–year 1.02% 3–month 0.09% Gross Expense Ratio as of 09/30/17 was 1.21% Net Expense Ratio as of 09/30/17 was 1.15%
NOV TPK MLUSG UGLD LLOBF RYAAY MTUAY MTUAF GE DSLV CSSLF USGPF ARNC DDAIF JBAXY GOOGL LLDTF TPRKY DGLD GOOG IPG CS BAC TVPKF GM USG ORCL JBARF GEC LLOY VIIX VIIZ RYAOF MA LYG NAPRF LLPH CSGKF LLPK LLPJ LLPE LLPD LLPG LLD5 GNE ZIV LLD7 LLPC USLV LLD6 TVIX LLD1 THC TV LLD2 XIV

13
Deals of the day-Mergers and acquisitions

2018-10-08 reuters
Oct 8 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 10:00 GMT on Monday:
LLOY LYG BHI LLPH LLPK LLPJ LLPE LLPD LLOBF PUK LLPG LLDTF LLD5 LLD7 LLPC LLD6 MYO LLD1 PUKPF LLD2

11
UPDATE 1-UK Stocks-Factors to watch on Oct 8

2018-10-08 reuters
Oct 8 (Reuters) - Britain’s FTSE 100 index is seen opening 5 points lower at 7,313 on Monday with FTSE 100 futures down 0.03 percent ahead of the cash market open, according to financial bookmakers.
LCSHF LLOY ABGLF LYG LLPH LLPK LLPJ ABGLY LLPE LLOBF LLPD PUK LLPG LLDTF LLD5 ACA LLD7 LLPC LLD6 LLD1 PUKPF LLD2

11
Schroders Plc and Lloyds Banking Group in talks over wealth management alliance

2018-10-07 channelnewsasia
Britain's Lloyds Banking Group is to merge its 13 billion pounds (US$17.06 billion) wealth management arm into a new joint venture with asset manager Schroders Plc , Sky news reported on Sunday.
SLFPF LLOY ADN SL LYG ABDNY LLPH LLPK LLPJ LLPE LLOBF LLPD LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 ABDNF LLD2 SLFPY

11
Schroders Plc and Lloyds Banking Group in talks over wealth management alliance

2018-10-07 reuters
(Reuters) - Asset manager Schroders Plc (SDR.L) and Lloyds Banking Group (LLOY.L) said on Sunday they were in discussions over a wealth management alliance.
SLFPF LLOY ADN SL LYG ABDNY LLPH LLPK LLPJ LLPE LLOBF LLPD LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 ABDNF LLD2 SLFPY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...